Ā | Eosinophilic asthma | Neutrophilic asthma | Mixed granulocytic asthma | Paucigranulocytic asthma | Healthy subjects | p value |
---|---|---|---|---|---|---|
N (% of asthmatics) | 350 (42) | 134 (16) | 31 (4) | 318 (38) | 194 | - |
Women, N (%) | 184 (53) | 95 (71)ā”ā | 19 (61) | 197 (62) | 105 (54) | 0.002 |
Age, years | 49 (34ā60)* | 52 (41ā61)ā”* | 61 (43ā71)ā”* | 43 (30ā54) | 45 (27ā56) | 0.0001 |
BMI | 25.9āĀ±ā4.9ā” | 25.3āĀ±ā5.4 | 25.5āĀ±ā4.6 | 26.1āĀ±ā4.8ā” | 24.3āĀ±ā4.1 | 0.0004 |
Atopy, N (%) | 213 (63)ā” | 69 (52)ā” | 17 (57)ā” | 165 (53)ā” | 46 (28) | <0.001 |
Smoking status, N (%) | Ā | Ā | Ā | Ā | Ā | Ā |
āNon-smokers | 190 (54) | 73 (55) | 19 (61) | 162 (52) | 109 (57) | >0.05 |
āCurrent smokers | 64 (18) | 26 (20) | 5 (16) | 76 (24) | 35 (18) | Ā |
āEx-smokers | 96 (27) | 33 (25) | 7 (23) | 75 (24) | 47 (25) | Ā |
FEV1, % predicted | 81.2āĀ±ā20.9ā”* | 81.6āĀ±ā22.0ā”* | 81.6āĀ±ā20.6ā” | 89.2āĀ±ā18.2ā” | 108.0āĀ±ā13.3 | 0.0001 |
FEV1/FVC, % | 70.7āĀ±ā11.1ā”* | 71.7āĀ±ā11.5ā”* | 70.1āĀ±ā10.5ā”* | 76.2āĀ±ā9.0ā” | 82.1āĀ±ā6.5 | 0.0001 |
FENO, ppb | 43 (23ā82)* | 20 (13ā33)ā Ā§ | 36 (21ā75)* | 16 (12ā29) | / | 0.0001 |
ICS therapy, N (%) | 227 (65) | 87 (65) | 18 (58) | 195 (61) | / | >0.05 |
ICS dosea | 500 (0ā1000) | 800 (0ā2000) | 800 (0ā1600) | 400 (0ā1000) | / | >0.05 |
OCS therapy, N (%) | 21 (6) | 9 (7) | 2 (6) | 14 (4) | / | >0.05 |
LABA, N (%) | 209 (60) | 80 (60) | 20 (65) | 181 (57) | / | >0.05 |
LTRA, N (%) | 75 (21) | 37 (28) | 9 (29) | 73 (23) | / | >0.05 |
Theophylline, N (%) | 11 (3) | 7 (5) | 0 (0) | 11 (3) | / | >0.05 |